Immunosequencing, the science of profiling T-cell receptors (TCRs) and B-cell receptors (BCRs), has been widely utilized to understand how the immune system changes in various disease states and how various treatment modalities impact immune responses. This webinar aims to provide an overview of Adaptive Biotechnologies’ immunoSEQ® Technology and cloud-based software, immunoSEQ Analyzer®. The webinar will cover functions of the Analyzer software and demonstrate how immunosequencing data can be incorporated into preclinical and clinical research with a focus on immuno-oncology and immunotherapy.
In this free webinar, the featured speakers will cover basic use of the Analyzer and how data is accessed and presented. Throughout the presentation, various tools and functionality within the software will be described and how they have been utilized in published studies. This will include a focus on preclinical models and how Adaptive’s technology has been applied to understand the immune repertoire of tumour-bearing mice. Furthermore, the attendees will hear how different treatments including targeted therapy, checkpoint inhibitors and combination therapy impact T-cell responses in the tumor microenvironment. The webinar will also extensively cover how immunoSEQ has been used to evaluate the immune repertoires of cancer patients in clinical trials. Examples will include repertoire data assessed at baseline, following therapeutic intervention, during the development of adverse events and tracking long-term repertoire properties and clones in patients.
Other topics of discussion include:
- Specific examples of how immunoSEQ was used to assess repertoire properties in pre-treatment tumor biopsies and how those findings were correlated with survival and response to checkpoint blockade
- How the Analyzer software can identify individual clones and track those clones in longitudinal samples
- Overview of data on patients who demonstrated adverse events in response to immunotherapy treatment and the repertoire properties associated with those toxicities
- How immunosequencing may be used to identify dominant clones in cellular infusion products, along with appropriate sequencing strategies for monitoring
- Overview of Adaptive’s immuneACCESS® portal, a free, online database containing thousands of samples worth of human and murine data that can be easily analyzed and incorporated into existing or future immunoSEQ projects
immunoSEQ is for Research Use Only. Not for use in diagnostic procedures.
Patrick Raber, PhD, Manager, Research and Business Development, Adaptive Biotechnologies
Dr. Patrick Raber is an immunologist with 12 years of research experience and is an expert in the field of immunosequencing. His current role at Adaptive Biotechnologies centers in the incorporation of immunosequencing into translational research and clinical trials for Adaptive’s academic research and biopharmaceutical partners focusing on the key elements of experimental design, data analysis and data interpretation. Dr. Raber holds a PhD in Immunology from the LSU Health Sciences Center in New Orleans where he focused on T-cell suppression in the tumor microenvironment by MDSCs and methods to improve adaptive cellular immunotherapies. He also holds a BS in Microbiology from the University of Georgia.
Who Should Attend?
This webinar will appeal to the following individuals:
- Academic and pharma oncology researchers
- Biomarker researchers
What You Will Learn
Attendees will learn how:
- Adaptive’s immunoSEQ technology can be used to quantitatively measure immune repertoire properties including diversity, clone tracking and repertoire overlap
- immunoSEQ has been extensively used to monitor repertoire properties in immuno-oncology including baseline assessments, response to therapy, correlation with adverse events and long-term monitoring
- The immunoSEQ Analyzer is a powerful, cloud-based software platform that enables researchers with both limited and advanced bioinformatic skillsets to access and analyze their immunoSEQ data
- Adaptive’s immuneACCESS portal is the world’s largest publicly available immunosequencing database that is free to use with thousands of samples of exportable data
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.